Valuation: Proteomics International Laboratories Ltd

Market Cap 19M 13.17M 11.52M 10.58M 9.87M 18.71M 1.25B 127M 49.4M 617M 49.45M 48.39M 2.12B P/E 2024
-17.4x
P/E 2025 -5.38x
Enterprise Value 8.24M 5.71M 4.99M 4.59M 4.28M 8.11M 544M 55.1M 21.42M 267M 21.44M 20.98M 921M EV / Sales 2024
33.2x
EV / Sales 2025 12.8x
Free-Float
74.46%
Yield 2024 *
-
Yield 2025 -
1 day-12.50%
1 week+62.79%
Current month+52.17%
1 month+29.63%
3 months-23.91%
6 months-72.22%
Current year-73.28%
1 week 0.1
Extreme 0.1
0.22
1 month 0.1
Extreme 0.098
0.22
Current year 0.1
Extreme 0.098
0.86
1 year 0.1
Extreme 0.098
0.86
3 years 0.1
Extreme 0.098
1.4
5 years 0.1
Extreme 0.098
1.4
10 years 0.1
Extreme 0.098
1.48
Manager TitleAgeSince
Chief Executive Officer - 2026-01-18
Director of Finance/CFO - 2026-04-16
Director of Finance/CFO - 2021-07-11
Director TitleAgeSince
Director/Board Member - 2017-11-21
Chairman 56 -
Director/Board Member - 2024-11-07
Date Insider Type Main position Quantity % Market Cap.
24-11-20Free

Founder

1,000,000 0.7633%
24-11-20Free

Founder

800,000 0.6107%
24-11-20Free

Founder

800,000 0.6107%
Change 5-day change 1-year change 3-year change Capi.($)
-12.50%+62.79%-58.82%-80.11% 22.91M
-2.14%+3.51%+74.50%+131.10% 59.1B
-0.93%+4.05%+73.64%+90.53% 55.19B
-2.62%+1.24%-13.28%-9.77% 24.67B
-0.47%+5.47%+13.94%+446.05% 24.19B
+0.64%+14.41%+44.27%-3.20% 19.69B
-2.19%+6.34%+39.72%-29.60% 17.56B
+3.58%+25.11%+196.41%+363.46% 16.22B
+4.91%+25.24%+44.61% - 14.84B
-0.47%+2.19%+25.61%+186.96% 14.04B
Average -1.20%+16.15%+44.06%+121.71% 24.55B
Weighted average by Cap. -0.61%+6.44%+58.05%+135.38%

Financials

2024 2025
Net sales 3.28M 2.27M 1.99M 1.83M 1.7M 3.23M 216M 21.92M 8.52M 106M 8.53M 8.35M 366M 3.31M 2.3M 2.01M 1.85M 1.72M 3.26M 219M 22.16M 8.61M 108M 8.62M 8.44M 371M
Net income -6.38M -4.42M -3.87M -3.55M -3.31M -6.28M -421M -42.65M -16.58M -207M -16.6M -16.24M -713M -8.11M -5.63M -4.92M -4.52M -4.21M -7.99M -536M -54.28M -21.1M -263M -21.12M -20.67M -908M
Net Debt -6.32M -4.39M -3.83M -3.52M -3.28M -6.23M -418M -42.3M -16.44M -205M -16.46M -16.11M -707M -10.76M -7.46M -6.52M -5.99M -5.59M -10.6M -710M -71.97M -27.98M -349M -28.01M -27.41M -1.2B
Logo Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd is an Australia-based medical technology company. The Company is engaged in predictive diagnostics and bioanalytical services. It specializes in the area of proteomics, the industrial scale study of the structure and function of proteins. It focuses on developing and commercializing diagnostic tests for chronic diseases. Its principal activities fall into three key areas: commercialization of PromarkerD, the predictive test for diabetic kidney disease (DKD) and future kidney function decline in patients with type 2 diabetes; precision diagnostic tests in development: the Promarker pipeline, and specialist accredited analytical services on a commercial basis. Its Promarker pipeline and analytical services include PromarkerEndo, PromarkerEso and OxiDx technology. PromarkerEndo is a prototype diagnostic test for endometriosis identifying up to 90% of patients with the disease. PromarkerEso is a prototype diagnostic test for esophageal cancer.
Employees
-
Date Price Change Volume
26-07-06 A$0.1750 -12.50% 1,732,111
26-07-03 A$0.2000 +25.00% 1,414,465
26-07-02 A$0.1600 +14.29% 885,305
26-07-01 A$0.1400 +21.74% 833,375
26-06-30 A$0.1150 +4.55% 1,207,893

Annual profits - Rate of surprise